Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease
Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00192-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/l...
12 Okt 202316min
Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction
Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00191-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://i...
13 Sep 202316min
Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis
Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00145-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... h...
10 Aug 202314min
Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease
Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00017-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ ...
12 Jul 202317min
Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis
Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00098-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on ...
7 Jun 202312min
Adelina Artenie on the incidence of HIV and HCV in people who inject drugs
Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00018-3/fulltext?dgcid=buzzsprout_icw_podcast_langas_lancet Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.c...
10 Mai 202317min
Johan Burisch on the costs of inflammatory bowel disease in high-income settings
Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings. Read the Commission here: The cost of inflammatory bowel disease in high-income settings Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com...
12 Apr 202320min
Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease. Read the full article: Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langa...
8 Feb 202321min
